---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-165812"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:52:42.520415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# ARS Pharmaceuticals stockholders elect three Class I directors, ratify EY as auditor at 2024 annual meeting

## Summary
- Shareholders elected Rajeev Dadoo, Michael Kelly, and Pratik Shah as Class I directors for terms expiring at 2027 annual meeting.
- Proposal to ratify Ernst & Young as independent auditor for FY 2024 passed with over 79.9M votes for, 0.03M against.
- Total shares outstanding and entitled to vote were 96,894,394 as of record date April 24, 2024.
- Broker non-votes were 7.6M to 7.8M on director elections, none on auditor ratification.
- All proposals received significant majority votes for.

## SEC filing metadata
- accession: 0001193125-24-165812
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312524165812/0001193125-24-165812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312524165812/d815026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-165812
- JSON: https://secwatch.observer/filing/0001193125-24-165812.json
- Plain text: https://secwatch.observer/filing/0001193125-24-165812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.